Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction

mRCC: Real-world experience: achieving efficacy beyond clinical trials

mRCC: Are we doing all we can to manage adverse events?

mRCC: Understanding the patient's perspective

mRCC: Panel discussion

mRCC: Closing remarks

Optimizing survival in advanced prostate cancer: Welcome and introduction

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future?